

Clinical Policy: Immunomodulators, Topical

Reference Number: PHW.PDL.153 Effective Date: 01/01/2020 Last Review Date: 11/2023

Policy/Criteria

Revision Log

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness[®] that Topical Immunomodulators are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Immunomodulators, Topical

A. Prescriptions That Require Prior Authorization

Requests for non-preferred Immunomodulators, Topical will require prior authorization.

B. Clinical Review Guidelines and Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for a non-preferred Immunomodulator, Topical, the determination of whether the requested prescription is medically necessary will take into account whether the recipient:

1. Has a history of therapeutic failure of a contraindication or an intolerance to the preferred Immunomodulators, Topical.

NOTE: If the member does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above, to assess the medical necessity of the request for a prescription for an Immunomodulator, Topical. If the guidelines in Section B are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the recipient.

D. <u>Approval Duration</u>:

• Duration of request or 12 months (whichever is less)

CLINICAL POLICY

Immunomodulators, Topical



Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021 annual review: no changes.	01/2021
Q3 2022: Updated wording per DHS	07/2022
Q1 2023 annual review: no changes.	11/2022
Q1 2024 annual review: no changes.	11/2023